tiprankstipranks
Trending News
More News >
Molecular Templates, Inc. (MTEMQ)
:MTEMQ
US Market

Molecular Templates (MTEMQ) Price & Analysis

Compare
563 Followers

MTEMQ Stock Chart & Stats


Options Prices

Currently, No data available
---

Ownership Overview

16.57%0.61%<0.01%83.43%
16.57%
Insiders
0.61%
Mutual Funds
<0.01% Other Institutional Investors
83.43% Public Companies and
Individual Investors

MTEMQ FAQ

What was Molecular Templates, Inc.’s price range in the past 12 months?
Molecular Templates, Inc. lowest stock price was $0.01 and its highest was $1.59 in the past 12 months.
    What is Molecular Templates, Inc.’s market cap?
    Molecular Templates, Inc.’s market cap is $658.00.
      When is Molecular Templates, Inc.’s upcoming earnings report date?
      Molecular Templates, Inc.’s upcoming earnings report date is Aug 07, 2025 which is in 31 days.
        How were Molecular Templates, Inc.’s earnings last quarter?
        Currently, no data Available
        Is Molecular Templates, Inc. overvalued?
        According to Wall Street analysts Molecular Templates, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Molecular Templates, Inc. pay dividends?
          Molecular Templates, Inc. does not currently pay dividends.
          What is Molecular Templates, Inc.’s EPS estimate?
          Molecular Templates, Inc.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Molecular Templates, Inc. have?
          Molecular Templates, Inc. has 6,583,880 shares outstanding.
            What happened to Molecular Templates, Inc.’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Molecular Templates, Inc.?
            Currently, no hedge funds are holding shares in MTEMQ

            Company Description

            Molecular Templates, Inc.

            Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
            Similar Stocks
            Company
            Price & Change
            Follow
            Fate Therapeutics
            Karyopharm Therapeutics
            Adaptimmune Therapeutics
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis